Genmab — April 2025
-
Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer https://www.onclive.com/view/second-line-sequencing-may-hinge-on-ihc-staining-in-cervical-cancer
-
The NCCN recommends tisotumab vedotin-tftv (Tivdak) as the only CATEGORY 1 PREFERRED option for second-line or subsequent therapy for recurrent or metastatic cervical cancer. https://www.tivdakhcp.com/
-
Genmabs schweiziske partner har fuld fart på salget af sklerosemiddel https://proinvestor.com/investornyt/1309398/genmabs-schweiziske-partner-har-fuld-fart-pa-salget-af-sklerosemiddel
-
-
New PhIII trial FILIOS started; for a new dosage of ofatumumab compared to the approved dosage https://www.novartis.com/sites/novartis_com/files/2025-04-interim-financial-report-en.pdf https://clinicaltrials.gov/study/NCT06869785
-
Novartis stops development of GIZ943 in ovarian and lung cancer. -, is a radioligand therapy that targets cells that express folate receptor alpha (FRα) https://www.fiercebiotech.com/biotech/novartis-axes-osteoarthritis-asset-and-radioligand-therapy-after-seeing-clinical-data
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind